米氮平在抑郁症治疗中的作用

被引:18
作者
司天梅
机构
[1] 北京大学精神卫生研究所卫生部精神卫生学重点实验室(北京大学)
关键词
D O I
暂无
中图分类号
R749.4 [情感性精神病];
学科分类号
摘要
<正>米氮平(美国默沙东公司;商品名:瑞美隆)是第一个去甲肾上腺素(NE)能和特异性5-羟色胺(5-HT)能抗抑郁药(NaSSA),美国精神病学学会(American PsychiatricAssociation)于2010年10月正式发布的第3版《抑郁症治疗指南》(以下简称《2010版指南》)中,将米氮平推荐为不同抑郁症治疗阶段以及多种特殊人群的治疗首选,米氮平的治疗学效果源于其独特的药理学特征。一、米氮平的特点与其他抗抑郁药相比,米氮平的药理学特点有:
引用
收藏
页码:116 / 117
相关论文
共 3 条
  • [1] Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression[J] . Michael E. Thase,Andrew A. Nierenberg,Peter Vrijland,Helga J.J. van Oers,Albert-Jan Schutte,John H. Simmons.International Clinical Psychopharmacology . 2010 (4)
  • [2] Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression[J] . Norio Watanabe,Ichiro M. Omori,Atsuo Nakagawa,Andrea Cipriani,Corrado Barbui,Hugh McGuire,Rachel Churchill,Toshi A. Furukawa.CNS Drugs . 2010 (1)
  • [3] Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis[J] . Andrea Cipriani,Toshiaki A Furukawa,Georgia Salanti,John R Geddes,Julian PT Higgins,Rachel Churchill,Norio Watanabe,Atsuo Nakagawa,Ichiro M Omori,Hugh McGuire,Michele Tansella,Corrado Barbui.The Lancet . 2009 (9665)